JPH02121910A - Cosmetic for pimple - Google Patents
Cosmetic for pimpleInfo
- Publication number
- JPH02121910A JPH02121910A JP27431488A JP27431488A JPH02121910A JP H02121910 A JPH02121910 A JP H02121910A JP 27431488 A JP27431488 A JP 27431488A JP 27431488 A JP27431488 A JP 27431488A JP H02121910 A JPH02121910 A JP H02121910A
- Authority
- JP
- Japan
- Prior art keywords
- acnes
- skin
- acne
- bacterium
- cell wall
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 45
- 239000002537 cosmetic Substances 0.000 title claims abstract description 10
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 25
- 241000186427 Cutibacterium acnes Species 0.000 claims abstract description 22
- 108010000912 Egg Proteins Proteins 0.000 claims abstract description 22
- 102000002322 Egg Proteins Human genes 0.000 claims abstract description 22
- 235000013345 egg yolk Nutrition 0.000 claims abstract description 21
- 210000002421 cell wall Anatomy 0.000 claims abstract description 18
- 235000013601 eggs Nutrition 0.000 claims abstract description 14
- 241000894006 Bacteria Species 0.000 claims abstract description 12
- 229940055019 propionibacterium acne Drugs 0.000 claims abstract description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 39
- 241000287828 Gallus gallus Species 0.000 claims description 17
- 235000013330 chicken meat Nutrition 0.000 claims description 17
- 230000000694 effects Effects 0.000 abstract description 18
- 210000004027 cell Anatomy 0.000 abstract description 13
- 208000020154 Acnes Diseases 0.000 abstract description 8
- 239000004615 ingredient Substances 0.000 abstract description 7
- 238000005119 centrifugation Methods 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 239000006228 supernatant Substances 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 16
- 230000003053 immunization Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 238000002649 immunization Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 7
- 239000007933 dermal patch Substances 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000006210 lotion Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000002884 skin cream Substances 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000012134 supernatant fraction Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 210000002976 pectoralis muscle Anatomy 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- VXYADVIJALMOEQ-UHFFFAOYSA-K tris(lactato)aluminium Chemical compound CC(O)C(=O)O[Al](OC(=O)C(C)O)OC(=O)C(C)O VXYADVIJALMOEQ-UHFFFAOYSA-K 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は、プロピオニバクテリウム・アクネス(以下■
3.アクネスと略記する)の細胞壁成分を免疫した鶏が
産生ずる卵より調製された卵黄抗体を含有することを特
徴とする新規なにきび用化粧料に関する。DETAILED DESCRIPTION OF THE INVENTION (Industrial Application Field) The present invention relates to Propionibacterium acnes (hereinafter referred to as
3. The present invention relates to a novel cosmetic for acne, characterized in that it contains an egg yolk antibody prepared from eggs produced by chickens immunized with cell wall components of acnes (abbreviated as acne).
(従来の技術及び発明が解決しようとする課B)にきび
は、皮膚の体裁を醜くし、かつしばしば厄介な症状を伴
い、皮脂腺に富む皮膚の成る領域、特に顔、頚、背に発
生する。にきびの発生原因は、主として、■皮脂の過剰
な分泌、■毛包脂腺系排出管の閉塞、■L包脂腺管内の
プロピオニバクテリウム戊の細菌(主として1″、アク
ネス)の(Y在などである。これらの発生囚fによって
、特徴的なにきびの面心、丘疹、1庖等の症状が現れる
。(Problem B that the Prior Art and Inventions Try to Solve) Acne, which disfigures the appearance of the skin and is often accompanied by troublesome symptoms, occurs in areas of skin rich in sebaceous glands, especially on the face, neck, and back. The causes of acne are mainly ■ Excessive secretion of sebum, ■ Blockage of the pilosebaceous drainage duct, and ■ Propionibacterium niobacterium (mainly 1″, acnes) bacteria (Y Due to these outbreaks, characteristic symptoms such as acne scars, papules, and pimples appear.
現在、上流を占めているにきびの−を防法、処置法或い
は治療法は、■過剰な皮脂の分lbを1印制すること、
■毛包の閉塞を除去すること、■細菌の増殖を抑制し、
更には殺菌処理を施すこと、■炎症作用をj巾側するこ
と等が挙げられる。The methods of preventing, treating, or treating acne, which is currently the most prevalent type of acne, are: - Applying 1 lb of excess sebum;
■Remove blockages in hair follicles, ■Inhibit bacterial growth,
Further examples include applying sterilization treatment, and (2) eliminating inflammatory effects.
抗体を応用した組成物としては、抗体及びこれを有効成
分とするスプレー剤(特開昭62175=126)、ト
リないしウシ抗体を用いた哺乳動物の受動免疫化方法及
びそのための組成物(特開昭6O−248628)があ
るが、第に細菌単独をニワトリ等の鳥類やウシ等の哺乳
ynに免疫しても、得られる抗体の細菌に対する制菌効
果等の直接的な効果は期待出来ず、P、アクネス等によ
り生ずるニキビの炎症には必ずしも効果的ではないのが
現状である。Examples of compositions using antibodies include antibodies and sprays containing the same as active ingredients (JP-A-62175-126), methods for passive immunization of mammals using avian or bovine antibodies, and compositions therefor (JP-A-62175=126); Firstly, even if birds such as chickens or mammals such as cows are immunized with bacteria alone, the resulting antibodies cannot be expected to have a direct effect such as bacteriostatic effect against the bacteria. Currently, it is not necessarily effective for acne inflammation caused by P. acnes and the like.
本発明は、皮膚刺激性が無く、にきびの治j寮に有効な
る作用を有する全く新しいにきび用化粧料を提供するこ
とを目的としている。The object of the present invention is to provide a completely new cosmetic for acne that is non-irritating to the skin and has an effective effect on the treatment of acne.
(課題を解決するための手段)
本発明は、皮膚の常在菌であるプロピオニバクテリウム
・アクネスの細胞壁成分を免疫した鶏が産生ずる卯より
調製された卵黄抗体を含有することを特徴とするにきび
用化粧r:1である。(Means for Solving the Problems) The present invention is characterized in that it contains an egg yolk antibody prepared from rabbits produced by chickens immunized with cell wall components of Propionibacterium acnes, which is a resident bacteria on the skin. Acne makeup r:1.
本発明に係るり11黄抗体は、P、アクネスの細胞壁成
分を免疫した鶏が産生ずる卵より容易に調製される。The Ruri 11 yellow antibody according to the present invention is easily prepared from eggs produced by chickens immunized with cell wall components of P. acnes.
ここで、本発明に使用するP、゛?アクネス、通常の嫌
寛性閑の培養に使用されるプレイン・ハート・インフュ
ージョン培地(B HI Iff地)などの液体培地を
用い、嫌気的に37℃で3〜lO口間培養することで培
養を行い、遠心分離することにより容易に得られる。Here, P used in the present invention, ゛? P. acnes, using a liquid medium such as plain heart infusion medium (BHI Iff medium), which is normally used for culturing a tolerogenic culture, by culturing anaerobically at 37°C for 3 to 100 g. can be easily obtained by centrifugation.
P、アクネスの細胞壁成分は、P、アクネスの菌体を2
0分〜1時間超音波破砕し、未破砕の菌体を遠心分離に
より除去した後の上滑分画中に得られる。この分画は、
DNa s e、RNa s e。The cell wall components of P. acnes are 2.
It is obtained in the supernatant fraction after ultrasonic disruption for 0 minutes to 1 hour and removal of undisrupted bacterial cells by centrifugation. This fraction is
DNase, RNase.
トリプシン、ゾロリ・−ゼで処理を行い、蛋白成分及び
核酸成分を除去することにより完全に可溶化される。こ
の分画は、更にセファデックスG100、セファロース
CL−6B等によるカラムクロ°7トグラフイーを行い
、免疫−次拡散法により、抗P、アクネス・ウサギ血清
抗体に対して陽性反応を示す分画を集めることで精製が
可能である。得られた細胞壁成分は、集めて蒸留水に対
して透析を行い、凍結乾燥により保存が可能である。It is completely solubilized by treatment with trypsin and Zorolize to remove protein and nucleic acid components. This fraction was further subjected to column chromatography using Sephadex G100, Sepharose CL-6B, etc., and fractions showing positive reactions to anti-P and acnes rabbit serum antibodies were collected by immuno-diffusion method. Purification is possible. The obtained cell wall components can be collected, dialyzed against distilled water, and stored by freeze-drying.
また、そのまま凍結保存することも可能である。It is also possible to freeze and preserve as is.
免疫操作に用いる鶏としては、特に制限はないが、抗体
の量産性という点からは、白色レグホンなどの卵用種を
用いるとよい。There are no particular restrictions on the chicken used for the immunization procedure, but from the standpoint of mass production of antibodies, egg-producing chickens such as white leghorn are preferably used.
また、免疫方法としては、皮下注射、腹腔的注射、筋肉
注射などによる通常の方法や、点鼻、点眼などの方法に
よって行うことができる。In addition, immunization can be carried out by conventional methods such as subcutaneous injection, intraperitoneal injection, and intramuscular injection, and methods such as nasal and eye drops.
更に、抗原の投与量は、所望の抗体値が得られ、かつ鶏
に対して悪影響を与えない量を適宜選択して用いればよ
い。また、必要に応じて完全フロインドアジュバント、
不完全フロインドアジュバントなどのアジュバントと併
用してもよい。Furthermore, the amount of antigen to be administered may be appropriately selected so that the desired antibody value is obtained and does not have an adverse effect on the chickens. In addition, complete Freund's adjuvant, if necessary.
It may be used in combination with an adjuvant such as incomplete Freund's adjuvant.
免疫後に、約2週間の間隔で抗体価をエンザイムイムノ
アノセイ、ラジオイムノアッセイ等の方法により6(す
定し、推移を追跡する。通常、初回免疫から数週間で投
与抗原に対して特異的に反応する抗体が卵(卵黄)中に
得られるが、通常約3ケ月間で抗体としての効果を発揮
するのに充分な高い抗体価をもつ抗体が得られる。なお
、免疫後、抗体価の減少が認められる場合、適当な間隔
で適宜追加免疫するごとにより抗体価を高めることがで
きる。After immunization, the antibody titer is determined at intervals of about 2 weeks by methods such as enzyme immunoassay and radioimmunoassay, and the progress is tracked.Usually, within a few weeks after the first immunization, the antibody titer becomes specific to the administered antigen. A reactive antibody is obtained in the egg (egg yolk), and it usually takes about 3 months to obtain an antibody with a high enough titer to be effective as an antibody.Please note that after immunization, the antibody titer decreases. If this is observed, the antibody titer can be increased by boosting at appropriate intervals.
本発明に係る卵黄抗体は、この、免疫した鶏が産生ずる
卯の卵黄より、クロロホルムを添加し、振とう、撹拌、
遠心分離を行うことにより脂質を除去した後の上清の水
溶液より得られ、蒸留水に対して透析後、濾過滅菌、凍
結乾燥等の操作により保存が可能である。得られた卵黄
抗体は白色から淡黄色を呈し、主として免疫グロブリン
(r −リヘチン)からなるタンパク質成分であるが、
その他β−2α−リベチン、オボアルブミンなどのタン
パク質成分も含有している。The egg yolk antibody according to the present invention is prepared by adding chloroform to the egg yolk produced by the immunized chicken, shaking, stirring,
It is obtained from an aqueous supernatant solution after lipids are removed by centrifugation, and can be preserved by dialysis against distilled water, sterilization by filtration, freeze-drying, and other operations. The obtained egg yolk antibody has a white to pale yellow color and is a protein component mainly composed of immunoglobulin (r-lihetin).
It also contains protein components such as β-2α-livetin and ovalbumin.
本発明に係る卵黄抗体は、未精製の状態でも使用するこ
とができるが、卵黄中に含まれる免疫グロフIJンを抽
出・分離することによって更に高い抗体価が得られる。Although the egg yolk antibody according to the present invention can be used in an unpurified state, a higher antibody titer can be obtained by extracting and separating the immunoglobulins contained in the egg yolk.
抽出・分離方法としては、硫酸アンモニウム、硫酸ナト
リウム等の塩類、またはデートストラン硫酸やポリエチ
レングリコール等の高分子化合物を用いた沈澱法や、D
EAIEセルロース等を用いるイオン交換クロマトグラ
フィーやセファロース類、セファデックス類等のゲル濾
過剤を用いるゲル濾過クロマトグラフィー等によっても
更に精製が可能である。その他、通常用いられている免
疫グロブリンを抽出・分離できる各種の方法等が利用で
きる。Extraction and separation methods include precipitation methods using salts such as ammonium sulfate and sodium sulfate, or polymeric compounds such as datetran sulfate and polyethylene glycol;
Further purification is also possible by ion exchange chromatography using EAIE cellulose or the like, gel filtration chromatography using a gel filtration agent such as Sepharose or Sephadex. In addition, various commonly used methods for extracting and separating immunoglobulins can be used.
本分画は、水溶性であり、最高で10!1fft%迄溶
解可能である。その他アルコールを含む水溶液にもン容
解が可能である。This fraction is water soluble and can dissolve up to 10!1 fft%. It can also be dissolved in aqueous solutions containing other alcohols.
本発明に係る卵黄抗体のP、アクネスに対する作用メカ
ニズムは次の如くに考えられる。P、アクネスの細胞壁
成分をニワトリに免疫して得られる卵黄抗体は、P、ア
クネスの表面に特巽的に結合して菌の活動や増殖を抑制
する。従って、P。The mechanism of action of the egg yolk antibody according to the present invention against P acnes is thought to be as follows. Egg yolk antibodies obtained by immunizing chickens with the cell wall components of P. acnes bind specifically to the surface of P. acnes and suppress the activity and proliferation of the bacteria. Therefore, P.
アクネスが菌体外に産生じ、皮膚内での炎症反応を増強
すると考えられている酸性多糖あるいはリパーゼ、酸性
ホスファターゼ、ヒアルロニダーゼ、プロテアーゼ、ニ
ューラミニダーゼなどの産生も結果的に抑制され、その
炎症の惹起能力を阻害或いは低下させることにより、優
れたにきび治療効果を発揮するものと推察される。As a result, the production of acid polysaccharides, lipase, acid phosphatase, hyaluronidase, protease, neuraminidase, etc., which are produced outside the bacterial cells and are thought to enhance the inflammatory response within the skin, is suppressed, and the inflammation is suppressed. It is presumed that by inhibiting or reducing the ability to induce acne, it exhibits excellent acne treatment effects.
本発明に係る卵黄抗体の配合量はにきび用化粧料(組成
物)の総量を基準として大略0. OOOl〜0.5型
組%(以下wt%と略記する)の範囲である。ここで、
卵黄抗体の配合量は、0.0001wt%未満では効果
が充分に達成されず、0.5wt%を超えてもその増加
分に見合った効果の向上は望めない。The blending amount of the egg yolk antibody according to the present invention is approximately 0.00% based on the total amount of the acne cosmetic (composition). It is in the range of OOOl to 0.5 mold type% (hereinafter abbreviated as wt%). here,
If the amount of egg yolk antibody added is less than 0.0001 wt%, the effect will not be sufficiently achieved, and if it exceeds 0.5 wt%, no improvement in effect commensurate with the increased amount can be expected.
更に、本発明のニキビ用化粧料は、通常使用される角質
溶解作用を有する成分として、レゾルノン、イオウ、ナ
リチル酸、尿素、イソプロピルメチルフェノール等、殺
菌作用を有する成分として、グルコン酸クロルヘキシジ
ン、塩酸クロル・\キンジン、塩化ヘンザルコニウム、
塩化ヘンザトニウム、その他の成分として、グリチルリ
チン、グリチルシー1゛ン酸、アラントイン、酸化亜鉛
、硫酸亜鉛、乳酸アルミニウム、乳酸エチル、エストラ
ジオール、カンフル、ビオチン等を同時に配合すること
も可能であり、その場合、より一層効果の増強が回持で
きる。また、その他の添加剤である抗酸化剤、香料、色
素、各種ビタミン類等を本発明の目的を達成する範囲で
適宜調製し配合することが可能である。Furthermore, the cosmetic for acne of the present invention contains commonly used ingredients with a keratolytic effect such as resolunon, sulfur, nalicylic acid, urea, and isopropylmethylphenol, and ingredients with a bactericidal effect such as chlorhexidine gluconate and chloride hydrochloride.・\Kinjin, henzalkonium chloride,
It is also possible to combine henzathonium chloride and other ingredients such as glycyrrhizin, glycyrrhizic acid, allantoin, zinc oxide, zinc sulfate, aluminum lactate, ethyl lactate, estradiol, camphor, biotin, etc. In that case, the The effect can be further enhanced. Further, other additives such as antioxidants, fragrances, pigments, various vitamins, etc. can be appropriately prepared and blended within a range that achieves the object of the present invention.
本発明のにきび用化粧料は、ローション類、乳液類、ク
リーム類、ゲル状物、スティック状物等の剤型に通常の
方法により調製することが可能である。The cosmetic for acne of the present invention can be prepared in the form of lotions, emulsions, creams, gels, sticks, etc. by a conventional method.
(実施例)
以下、実施例、比較例の記載に基づいて本発明を詳説す
る。実施例に記載したヒト皮膚貼付試験、にきびの治療
効果試験は下記の通りである。(Examples) Hereinafter, the present invention will be explained in detail based on the descriptions of Examples and Comparative Examples. The human skin patch test and acne treatment effect test described in the Examples are as follows.
il+ ヒト皮膚貼付試験
vl、驕者25名の前腕圧側部皮膚に、試#40.05
gを直径1.9 c mの円形のろ紙のついた貼付試験
用絆創膏を用いて24時間の閉塞貼付を行った。il+ Human skin patch test vl, Test #40.05 was applied to the skin of the side of the forearm of 25 people.
g was occlusively applied for 24 hours using a test adhesive plaster with a circular filter paper of 1.9 cm in diameter.
次いで、下記第1表の判定基準に従って、絆創膏除去1
時間後、24時間後の判定を実施した0判定結果は、反
応の強い方の評価を採用し、被験者25名のうら評価が
(±)以上と判定された人の数で示した。Next, bandage removal 1 according to the criteria in Table 1 below.
The 0 judgment results obtained after 24 hours and 24 hours were evaluated based on the stronger reaction, and were expressed as the number of 25 subjects whose back evaluation was (±) or higher.
第 1 表
(2) にきび治療効果試験
顔面かにきび症状を有する被験者の左部に対照品(基剤
のみの組成物)を、右部には実施例成いは比較例の試験
品を各々10に朝夕2回づつ1ケ月間連続塗布した。次
いで、にきび疾患部の治療効果を下記第2表の判定基t
pに従って、半間比較法により判定した0判定結果は、
評価点の平均値で示した。Table 1 (2) Acne treatment effect test A control product (base only composition) was placed on the left side of a test subject with facial acne symptoms, and 10 test items of Examples or Comparative Examples were placed on the right side. I applied it continuously for 1 month, twice in the morning and once in the evening. Next, the therapeutic effect on acne diseased areas was evaluated using the criteria t in Table 2 below.
According to p, the 0 judgment result judged by the half-time comparison method is
It is shown as the average value of evaluation points.
第 2 表 〔卵黄抗体の調製〕 実施例、比較例に係るP、アクネス及びP。Table 2 [Preparation of egg yolk antibody] P, acnes and P according to Examples and Comparative Examples.
クネスの細胞壁成分の調製、鶏に対する免疫、黄抗体の
調製の例を示す。Examples of preparation of cell wall components of Knes, immunization of chickens, and preparation of yellow antibodies are shown.
1、P、アクネスの菌体の調製
G・パブ口らの方法(ジャーナル・オブインベスティゲ
イティブ・デルマトロジー、63S、231−238頁
、1974年)に従って、[3HI液体培地(デイフコ
社製、51)を用いて、P。1. Preparation of P. acnes bacteria according to the method of G. Pabguchi et al. (Journal of Investigative Dermatology, 63S, pp. 231-238, 1974). 51) using P.
アクネスを嫌気的に37℃で5日間培養し、遠心分離に
より菌体を18養上清と分離した(菌体湿重量: a、
5 g )。P. acnes was cultured anaerobically at 37°C for 5 days, and the bacterial cells were separated from the 18 culture supernatant by centrifugation (wet weight of bacterial cells: a,
5g).
2、P、アクネスの細胞壁成分の調製
次に、G・ウェブスターらの方法(ジャーナル・オブ・
インへスティゲイティブ・ゲルマトロジー84巻、49
6−500頁、1985年)によりP、アクネス細胞壁
成分の調製を行った。P、アクネス5gを生理食塩水に
懸濁させ、超音波破砕を行なった(100mW、1時間
)。次に、200Orpm、10分間の条件で遠心分離
を行い沈澱分画中の未破砕の菌体を除去した。上清分画
は史に15000rpm、30分間の条件で遠心分離を
行い、沈澱分画中に細胞壁分画を得た。2. Preparation of cell wall components of P. acnes Next, the method of G. Webster et al. (Journal of
Investigative Germatology Volume 84, 49
6-500, 1985), P. acnes cell wall components were prepared. 5 g of P. acnes was suspended in physiological saline and subjected to ultrasonic disruption (100 mW, 1 hour). Next, centrifugation was performed at 200 rpm for 10 minutes to remove unbroken bacterial cells in the precipitate fraction. The supernatant fraction was centrifuged at 15,000 rpm for 30 minutes to obtain a cell wall fraction among the precipitate fractions.
この分画は、DNa s e、RNa s e、 ト
リプシン、プロナーゼで処理を行い、蛋白成分及び核酸
成分を除去し完全に可溶化し、生理食塩水に対して透析
を行った。この分画は、更にセファロースCLdBカラ
ムクロマトグラフィー(2,5X60 c m、0.
I 5 M N a CR、p H7,2)により、精
製を行lっだ。オフタロニー法により、P、アクネス全
菌体に対するウサギ血清抗体を用いて抗原活性を調べた
結果、K a V = 0.21−0.50に抗原のピ
ークが認められたので、この分画を集めて濃縮、凍結乾
燥し、細閑壁分画を得た(収量536mg)、本市の分
析値は、糖含有量二81.2%(フェノール硫酸法)、
蛋白含有量11.4%(ローリ−・フォーリン法)。This fraction was treated with DNase, RNase, trypsin, and pronase to remove protein and nucleic acid components and completely solubilized, and then dialyzed against physiological saline. This fraction was further purified by Sepharose CLdB column chromatography (2.5 x 60 cm, 0.5 x 60 cm).
Purification was carried out by I 5 M Na CR, pH 7,2). As a result of examining the antigen activity using rabbit serum antibodies against whole P. acnes cells by the ophthalony method, an antigen peak was observed at K a V = 0.21-0.50, so this fraction was collected. It was concentrated and lyophilized to obtain a thin wall fraction (yield: 536 mg). Motoichi's analytical values showed that the sugar content was 281.2% (phenol-sulfuric acid method);
Protein content 11.4% (Lori-Forin method).
3−1.細胞壁成分の鶏に対する免疫
上記の方法で得られたP、アクネスの細胞壁成分を、5
m g / sn j!の濃度で生理食塩水に溶解し
た。次に完全フロインドアジュバントとtitに混和し
、完全なエマルジョンを調製した。これらのエマルジョ
ンを約1.5ケ月〜2ケ月令の雌の鶏の左右の胸筋にQ
、 5 m ilづつを筋肉性1・jシた(1群10羽
) 1ケ月後に1.同量の試料を再び筋肉ン主射した
。3-1. Immunization of cell wall components to chickens The cell wall components of P. acnes obtained by the above method were
m g / sn j! Dissolved in physiological saline at a concentration of The mixture was then mixed with complete Freund's adjuvant to prepare a complete emulsion. Apply these emulsions to the left and right pectoral muscles of female chickens approximately 1.5 to 2 months old.
After 1 month, 1.5 ml of muscular 1.j. The same amount of sample was again injected into the muscle.
3−2.P、アクネス全菌体の鶏に対する免疫対照とし
て、予め70℃、3時間で熱処理した1)、アクネス全
菌体を2XIO’ コ/ m 1を上記免疫方法と同様
にして、別の実験群の鶏10羽に免疫した。1ケ月後に
、同所の試料を再び筋肉注射した。3-2. As a control for immunizing chickens with P. acnes whole cells, 1) P. acnes whole cells, which had been heat-treated in advance at 70°C for 3 hours, were immunized at 2XIO'co/m1 in the same manner as the above immunization method, and in another experimental group. Ten chickens were immunized. One month later, the same site samples were injected intramuscularly again.
4、抗体価のdull定
免疫操作した鶏が、免疫開始前1週間、2ケ月目より1
週間、3ケ月目より1週間の期間に産生じた卵を、それ
ぞれ免疫前、2ケ月目、3ケ月目の卵として抗体値の測
定に用いた。抗体分画の調製は以下の様にして行った。4. Dull immunized chickens with constant antibody titers were tested 1 week before the start of immunization and 1 week after the 2nd month.
Eggs produced during the period of one week from the third month and the third month were used to measure the antibody level as eggs before immunization, eggs from the second month, and eggs from the third month, respectively. Antibody fractions were prepared as follows.
卵の卵黄を採取し、その間l鋒の生理食塩水を加え、室
温で5分間振とうし、更に元の卵黄の2倍量のクロロホ
ルムを加え、30分間の振とう、撹拌を行った。得られ
たエマルジョンを室温で30分間放置し、3000rp
mで20分間遠心分離し、上清液を採取し、濾過滅菌し
て抗体分画を得た。抗体価の推移は、常法に従ってエン
ザイムイムノアノセイのうちのELIS八により追跡を
行い、免疫前、2ケ月目、3ケ月目の抗体価を第3表に
示した。その結果、細胞壁成分の方が、抗体価の上昇性
が高く、3ケ月後ではP、アクネス全菌体の約4倍の値
を示した。The yolks of the eggs were collected, during which time one volume of physiological saline was added, and the mixture was shaken at room temperature for 5 minutes. Then, twice the amount of chloroform as the original yolk was added, and the mixture was shaken and stirred for 30 minutes. The resulting emulsion was left at room temperature for 30 minutes and then heated at 3000 rpm.
The supernatant was collected and filter-sterilized to obtain an antibody fraction. The changes in the antibody titer were tracked using ELIS 8 of enzyme immunoassay according to the conventional method, and the antibody titers before immunization, 2 months, and 3 months are shown in Table 3. As a result, the cell wall component showed a higher rise in antibody titer, and after 3 months, the value of P. acnes was about 4 times higher than that of the whole bacterial cells.
第 3 表
5、卵黄抗体の調製
次に、免疫操作開始後3ケ月目より1ケ月間の期間に鶏
が産生した卵の卵黄を採取し、「4.抗体価の測定Jの
項で記述した通りに抗体分画を得た。Table 3. Preparation of egg yolk antibodies Next, the yolks of eggs produced by chickens during a period of 1 month from the 3rd month after the start of immunization were collected, and the yolks were collected as described in ``4. Measurement of antibody titer J''. Antibody fractions were obtained as described.
更に、この抗体分画を、硫酸アンモニウムの40%飽和
濃度により沈澱として回収し、生理食塩水に対して透析
した後、再び硫酸アンモニウムの35%飽和濃度により
沈澱として回収し、蒸留水に対して48時間透析した後
、凍結乾燥して精製された卵黄抗体を得た。得られた乾
燥抗体は、硫酸アンモニウムによう沈′R操作を行lう
前の抗体分画の量になるように生理食塩水により再溶解
し、これを原液としてEL I SAにより抗体価を測
定した。その結果を第4表に示す。Furthermore, this antibody fraction was collected as a precipitate using ammonium sulfate at a 40% saturation concentration, dialyzed against physiological saline, recovered as a precipitate again using a 35% saturation concentration of ammonium sulfate, and dialyzed against distilled water for 48 hours. After dialysis, purified egg yolk antibodies were obtained by freeze-drying. The obtained dried antibody was redissolved in physiological saline to the same amount as the antibody fraction before the precipitation procedure with ammonium sulfate, and the antibody titer was measured by ELISA using this stock solution. . The results are shown in Table 4.
第 4 表
実施例1〜7、比較例1〜4
〔にきび用ローション〕
にきび川口−ノヨン基剤に前記(卵殻tiL体の調製)
の項でil)られた1)、アクネスの細胞壁成分に封す
る卵黄抗体(実施例、以下抗細胞壁抗体と略記する)、
または1)、アクネスの全菌体に対する卵Cα抗体(比
較例、以下抗仝菌抗体と略記する)をそれぞれ第5表に
記載の如(配合した各試料を調製し、試験に(支出した
。Table 4 Examples 1 to 7, Comparative Examples 1 to 4 [Acne lotion] Acne Kawaguchi-Noyon base and the above (preparation of eggshell tiL body)
1), egg yolk antibody encapsulated in acne cell wall components (example, hereinafter abbreviated as anti-cell wall antibody), as described in section 1);
Alternatively, 1), egg Cα antibodies (comparative examples, hereinafter abbreviated as anti-bacterial antibodies) against all bacterial cells of P. acnes were prepared and tested as shown in Table 5.
(1) 組成 第 5 表
(2) 調製法
第5表に示すエタノール、可溶化剤、プロピレングリコ
ールを、必要に応じて加熱して精製水に溶解した後、5
0℃まで冷却した0次に、卵黄抗体を添加し、組成総量
が100wt%となるように調製された残量の精製水を
加えて均一に混合し、各にきび用ローションを調製した
。(1) Composition Table 5 (2) Preparation method After dissolving the ethanol, solubilizer, and propylene glycol shown in Table 5 in purified water by heating as necessary,
Next, the egg yolk antibody was added to the mixture, which was cooled to 0° C., and the remaining amount of purified water adjusted to have a total composition of 100 wt% was added and mixed uniformly to prepare each acne lotion.
(3) 特性
実施例1〜7、比較例1〜4のにきび治療効果試験の結
果を第6表に示す。(3) Characteristics Table 6 shows the results of the acne treatment efficacy test for Examples 1 to 7 and Comparative Examples 1 to 4.
第6表に示す如く、実施例1〜7の抗細胞壁抗体を配合
したにきび用ローションは、明らかに高いにきび治療効
果が認められた。また、ヒト皮膚貼付試験における皮膚
刺激性は認められなかった。As shown in Table 6, the acne lotions containing the anti-cell wall antibodies of Examples 1 to 7 were clearly found to have high acne treatment effects. In addition, no skin irritation was observed in human skin patch tests.
一方、比較例1〜4の抗全菌抗体を配合したにきび用ロ
ーションは、にきび治療効果が低く、且つヒト皮膚貼付
試験における皮膚刺激性も高かった。On the other hand, the acne lotions containing the anti-total bacterial antibodies of Comparative Examples 1 to 4 had low acne treatment effects and high skin irritation in human skin patch tests.
実施例8〜14、比較例5〜8
〔にきび用スキンクリーム〕
にきび用スキンクリーム基剤に本発明に係る卵仏抗体を
第7表に記載の如く配合した各試料を調(11組成
第
表
(2) 調製法
第7表のB及びC成分を、各々80℃に加熱溶解したも
のをlX1合した後、撹拌しつつ50℃まで冷却した。Examples 8 to 14, Comparative Examples 5 to 8 [Skin cream for acne] Each sample was prepared by blending the eggplant antibody according to the present invention into a skin cream base for acne as shown in Table 7 (11 Composition Table 7) (2) Preparation method Ingredients B and C in Table 7 were heated and dissolved at 80°C and combined in 1×1 volume, and then cooled to 50°C with stirring.
次に、A成分添加して30℃まで撹(Irを続け、各に
きび用スートンクリームを調製した。Next, component A was added and stirred to 30° C. (Ir was continued) to prepare each suton cream for acne.
(3) 特性
実施例8〜14、比較例5〜8のにきび治療効果試験の
結果を第8表に示す。(3) Properties Table 8 shows the results of the acne treatment efficacy test for Examples 8 to 14 and Comparative Examples 5 to 8.
第8表に示す如く、実施例8〜14の抗細胞壁抗体を配
合したにきび用スキンクリームは、明らかに高いにきび
治療効果が認められた。また、ヒト皮膚貼付試験におけ
る皮膚刺激性は認められなかった。一方、比較例5〜8
の抗全菌抗体を配合したにきび用スキンクリームは、に
きび治療効果が低く、且つヒト皮膚貼付試験における皮
膚刺激性も高かった。As shown in Table 8, the skin creams for acne containing the anti-cell wall antibodies of Examples 8 to 14 were clearly found to have high acne treatment effects. In addition, no skin irritation was observed in human skin patch tests. On the other hand, Comparative Examples 5 to 8
A skin cream for acne containing anti-all-bacterial antibodies had low acne treatment efficacy and high skin irritation in human skin patch tests.
(発明の効果)
本発明のにきび用化粧料は、皮膚刺激性が無く、にきび
の予防、治療に有効なる作用を有し、且°つ、長期間保
存しても安定であって、その商品価値は掻めて高い。(Effects of the Invention) The cosmetic for acne of the present invention is non-irritating to the skin, has effective effects on preventing and treating acne, and is stable even when stored for a long period of time. The value is extremely high.
Claims (1)
の細胞壁成分を免疫した鶏が産生する卵より調製された
卵黄抗体を含有することを特徴とするにきび用化粧料。A cosmetic for acne, characterized by containing an egg yolk antibody prepared from eggs produced by chickens immunized with cell wall components of Propionibacterium acnes, which is a resident bacteria of the skin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP27431488A JPH02121910A (en) | 1988-10-28 | 1988-10-28 | Cosmetic for pimple |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP27431488A JPH02121910A (en) | 1988-10-28 | 1988-10-28 | Cosmetic for pimple |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH02121910A true JPH02121910A (en) | 1990-05-09 |
Family
ID=17539922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP27431488A Pending JPH02121910A (en) | 1988-10-28 | 1988-10-28 | Cosmetic for pimple |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH02121910A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100392566B1 (en) * | 2001-11-13 | 2003-07-23 | 주식회사 에그 바이오택 | THE PRODUCTION METHOD OF EGG CONTAINING MIXING IgY ABOUT Propionibacterium acnes, Staphylococcus epidermidis, E.coli CAUSING ACNES AND THEREOF PREVENTING COSMETICS FOR ACNES SKIN CONTAINING MIXING IgY |
KR20040005541A (en) * | 2002-07-10 | 2004-01-16 | 선우선영 | The effective producing method of anti-acnes IgYs in several form. |
WO2006022409A1 (en) * | 2004-08-27 | 2006-03-02 | Daikin Industries, Ltd. | Hazardous substance scavenger and application apparatus and application method therefor |
WO2013027356A1 (en) * | 2011-08-19 | 2013-02-28 | オーストリッチファーマ株式会社 | Antibody and antibody-containing composition |
CN109963867A (en) * | 2016-06-13 | 2019-07-02 | E&S医疗保健有限公司 | Pass through the human antibody and application thereof of display technique of bacteriophage and acne bacteria specific binding |
CN113171333A (en) * | 2021-04-25 | 2021-07-27 | 大连大学 | Multi-effect repairing mask liquid containing nano embedded yolk antibody and preparation method thereof |
-
1988
- 1988-10-28 JP JP27431488A patent/JPH02121910A/en active Pending
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100392566B1 (en) * | 2001-11-13 | 2003-07-23 | 주식회사 에그 바이오택 | THE PRODUCTION METHOD OF EGG CONTAINING MIXING IgY ABOUT Propionibacterium acnes, Staphylococcus epidermidis, E.coli CAUSING ACNES AND THEREOF PREVENTING COSMETICS FOR ACNES SKIN CONTAINING MIXING IgY |
KR20040005541A (en) * | 2002-07-10 | 2004-01-16 | 선우선영 | The effective producing method of anti-acnes IgYs in several form. |
WO2006022409A1 (en) * | 2004-08-27 | 2006-03-02 | Daikin Industries, Ltd. | Hazardous substance scavenger and application apparatus and application method therefor |
US9828419B2 (en) | 2011-08-19 | 2017-11-28 | Ostrich Pharma Kk | Antibody and antibody-containing composition |
JPWO2013027356A1 (en) * | 2011-08-19 | 2015-03-05 | オーストリッチファーマ株式会社 | Antibody and antibody-containing composition |
AU2012298125B2 (en) * | 2011-08-19 | 2015-09-24 | Immortal Spirit Limited | Antibody and antibody-containing composition |
WO2013027356A1 (en) * | 2011-08-19 | 2013-02-28 | オーストリッチファーマ株式会社 | Antibody and antibody-containing composition |
US10106599B2 (en) | 2011-08-19 | 2018-10-23 | Ostrich Pharma Kk | Antibody and antibody-containing composition |
EP3406716A1 (en) * | 2011-08-19 | 2018-11-28 | Ostrich Pharma KK | Antibody and antibody-containing composition |
US10428138B2 (en) | 2011-08-19 | 2019-10-01 | Ostrich Pharma Kk | Antibody and antibody-containing composition |
US11041016B2 (en) | 2011-08-19 | 2021-06-22 | Ostrich Pharma Kk | Compositions containing anti-HIV ostrich antibodies |
CN109963867A (en) * | 2016-06-13 | 2019-07-02 | E&S医疗保健有限公司 | Pass through the human antibody and application thereof of display technique of bacteriophage and acne bacteria specific binding |
CN113171333A (en) * | 2021-04-25 | 2021-07-27 | 大连大学 | Multi-effect repairing mask liquid containing nano embedded yolk antibody and preparation method thereof |
CN113171333B (en) * | 2021-04-25 | 2024-02-13 | 大连大学 | Multi-effect repairing mask liquid containing nano embedded egg yolk antibody and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5037803A (en) | Product comprising a silicon organic compound combined with a cosmetically active substance | |
CN109498494A (en) | A kind of salubrious oil-control is without silicone oil shampoo and preparation method thereof | |
US9649512B2 (en) | One or more of Vigna marina, Cocos nucifera L. or Terminalia catappa L. extracts for treating wounds, skin disorders and hair loss | |
WO2019013670A1 (en) | Cosmetic mask for application to the skin, and method for applying same | |
JP2021526154A (en) | Composition for muscle relaxation | |
JP3434333B2 (en) | Skin preparation | |
JP3556595B2 (en) | Cosmetic composition for skin protection containing retinol and epidermal growth factor | |
JPS6219511A (en) | Cosmetic for preventing aging of skin | |
JPH02121910A (en) | Cosmetic for pimple | |
JP2567317B2 (en) | Hair cosmetics | |
JPH09301819A (en) | Cosmetic containing enka-extract | |
JP3073862B2 (en) | Hyaluronic acid production promoter | |
JPH02121908A (en) | Cosmetic for pimple | |
JPS63150210A (en) | Hair-tonic cosmetic | |
JPH02121909A (en) | Cosmetic for pimple | |
WO2007144723A2 (en) | Use of plants of carpobrotus edulis as anti-itching and/or anti-inflammatory agents | |
JP2834278B2 (en) | Cosmetic and external preparation for skin | |
JPH0412243B2 (en) | ||
JP2002316943A (en) | Anti-acne composition and cosmetic containing the same and used for acne | |
JP3172599B2 (en) | Cell activator | |
JPH0665041A (en) | Skin external preparation | |
US5190916A (en) | Use of ovomacroglobulin as an agent for treating wound and inflammation | |
JPH0853326A (en) | Cosmetic for hair | |
JPH10182409A (en) | Cosmetic | |
JPH01313439A (en) | Anti-acne vulgaris bacteria skin drug for external use |